China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Asian Stocks Slide as Iran Tensions Escalate Despite Strong Weekly Gains 
Trump-Xi Meeting 2026: U.S.-China Trade Tensions Escalate Ahead of Beijing Summit 
US-Iran Ceasefire Under Pressure as Fresh Strait of Hormuz Clashes Shake Oil Markets 
Japan Tech Stocks Surge as AI Optimism Lifts SoftBank, Chipmakers 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
Armani Group Eyes Strategic Stake Sale to Luxury Giants 
Trump Signals Possible U.S.-Iran Peace Deal as Markets Rally on Hopes of War Ending 
Oil Prices Surge as U.S.-Iran Conflict Threatens Strait of Hormuz Supply Route 
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone 
European Stocks Fall as US-Iran Conflict Rekindles Energy Supply Fears 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Russian LNG Shadow Fleet Expands Amid Arctic LNG 2 Sanctions 
Samsung Biologics signed a contract manufacturing organization (CMO) deal with GreenLight Biosciences to produce COVID-19 vaccines for poor nations, particularly in Africa. The South Korean pharma company revealed its new partnership agreement with the Boston-based biotech firm on Thursday, Nov. 25.
Samsung Biologics and GreenLight Biosciences’ goal is to bring vaccines to everyone as they want to have a world that has the ability to produce sufficient messenger RNA vaccine doses for billions of people per year.
As per The Korea Herald, the agreement between the companies stated that the Korean pharma company would produce drug materials for GreenLight’s COVID-19 vaccine candidate. The two firms also agreed to scale up research and manufacturing efforts so they can be able to allocate more coronavirus vaccines for underdeveloped countries.
Samsung’s pharma unit added that it would be expanding its production plant in Songdo, Incheon, by building new facilities on the site. The constructions are expected to be completed by April next year.
“We are delighted to partner with GreenLight to leverage our expertise in manufacturing a messenger RNA COVID-19 vaccine candidate to better serve patients in lower income countries,” Samsung Biologics chief executive officer, John Rim, said in a press release. “This collaboration demonstrates a major milestone for Samsung Biologics as we will commence our expanded capabilities and operations to provide one-stop end-to-end messenger RNA production from Drug Substance (DS) to Aseptic Fill Finish (DP) to commercial release, all from a single site.”
Meanwhile, GreenLight Biosciences is also reported to be in the last stage of finalizing its partnership deal with a local partner in Africa. This is a separate agreement with Samsung Biologics, and after the contracts are sealed, the American biotech company is planning to start the phase 1 clinical trials for its vaccine candidate as early as the first quarter of 2022, as per Korea Joongang Daily.
Samsung Biologics and GreenLight Biosciences are producing COVID-19 vaccines using mRNA or messenger ribonucleic acid. This is the same type applied to Pfizer and Moderna vaccines.
Finally, Andrey Zarur, GreenLight CEO, said they are happy to join forces with Samsung to make messenger RNA for their Covid vaccine trial as there is an urgent need to develop vaccines for the whole world.
